HHS-OIG rule RIN-936-AAO8,Removal of Safe Harbor Protections for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection.
HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Duration: February 1, 2012
to
February 1, 2019
General Issues: Medicare/Medicaid , Health Issues , Pharmacy , Postal
Spending: about $770,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2012: U.S. Senate, House of Representatives, Centers For Medicare and Medicaid Services (CMS), Centers For Medicare and Medicaid Services (CMS), Centers For Medicare and Medicaid Services (CMS),, Office of Personnel Management (OPM), Health & Human Services - Dept of (HHS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Henry W Menn III
Sp Asst Leg Aff, FDA Off of Commiss(93-95);
CoS, Sen Bob Graham(01-04);
Min SD & Counsel Cmte on Vet Affairs (04)
Min SD & Counsel, Cmte on Vet Affairs (04)
Micahel Lewan
CoS, Rep Solarz(88); CoS, Sen Lieberman(89-93)
Lisa Layman
CBO, PA(92-96); LA, Sen Chafee(97-99);
LA, Sen Bryan(00); SPA, Sen Graham(01-04);
SPA, Sen Stabenow(05-07)
SPA, Sen Stabenow (2005-2007); SPA, Sen Graham (2001 - 2004); LA, Sen Bryan (2000); LA, Sen Chafee (1997 - 1999); CBO, PA (1992 - 1996)
SPA, Sen. Stabenow (05-07)
Henry Menn III
CoS, Sen. Bob Graham (2001 - 2004); Min SD & Counsel, Cmte on Vet Affairs (2004); Sp Asst Leg Aff, FDA Office of Commissioner (1993-1995)
Sp Asst Leg Aff, FDA Off of Commiss(93-95);
CoS, Sen Bob Graham(01-04);
Min SD & Counsel, Cmte on Vet Affairs (04)
CoS, Sen. Bob Graham (01 - 04)
Michael Lewan
CoS, Rep Solarz(88); CoS, Sen Lieberman(89-93)
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2019
Brown Rudnick LLP terminated an engagement in which they represented Prime Therapeutics on Feb. 8, 2019.
Original Filing: 301020064.xml
Lobbying Issues
HHS-OIG rule RIN-936-AAO8,Removal of Safe Harbor Protections for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2018
In Q4, Brown Rudnick LLP lobbied for Prime Therapeutics , earning $30,000. The report was filed on Jan. 20, 2019.
Original Filing: 301011149.xml
Lobbying Issues
H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR); S.771 & H.R. 1776-Improving Access to Affordable Prescription Drugs Act; H.R.1316-The Prescription Drug Price Transparency Act; HHS-OIG rule RIN -936-AAO8 entitled, Removal of Safe Harbor Protections for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 2212 & S. 974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES);HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2018
In Q3, Brown Rudnick LLP lobbied for Prime Therapeutics , earning $30,000. The report was filed on Oct. 10, 2018.
Original Filing: 300984013.xml
Lobbying Issues
H.R. 1316-The Prescription Drug Price Transparency Act (MAC);H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR);S. 2553-Know the Lowest Price Act;Proposed HHS-OIG rule RIN -936-AAO8 under OMB review entitled, Removal of Safe Harbor Protections for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection.;H.R. 6-SUPPORT for Patients and Communities Act relating to S.2460 & H.R. 3528 (Every Prescription Controlled Securely Act);
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 2212 & S. 974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; H.R.6641-The COST Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S. 2554-Patient Right to Know Drug Prices Act; H.R. 5343-Prescription Transparency Act of 2018.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2018
In Q2, Brown Rudnick LLP lobbied for Prime Therapeutics , earning $30,000. The report was filed on July 12, 2018.
Original Filing: 300964187.xml
Lobbying Issues
H.R. 1316-The Prescription Drug Price Transparency Act (MAC); H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR); H.R. 1939 & S. 1044 - Ensuring Seniors Access to Local Pharmacies Act of 2017; S. 2553-Know the Lowest Price Act. CY2019 Medicare Part D Final Rule relating to direct and indirect renumeration fees; H.R.5958-The Phair Pricing Act of 2018.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 2212 & S. 974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; H.R. 3528 & S. 2460-Every Prescription Conveyed Securely Act (e-prescribing).H.R.6-SUPPORT for Patients and Communities Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S. 2554-Patient Right to Know Drug Prices Act; H.R. 5343-Prescription Transparency Act of 2018.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2018
In Q1, Brown Rudnick LLP lobbied for Prime Therapeutics , earning $30,000. The report was filed on April 19, 2018.
Original Filing: 300950736.xml
Lobbying Issues
H.R. 1316-The Prescription Drug Price Transparency Act (MAC); H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR); H.R. 1939 & S. 1044 - Ensuring Seniors Access to Local Pharmacies Act of 2017; S.637-Creating Transparency to Have Drug Rebates Unlocked Act of 2017. S. 2553-Know the Lowest Price Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 2212 & S. 974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; Issues relating to regulation of biosimilars; S. 771 & H.R. 1776-Improving Access to Affordable Prescription Drugs Act; H.R. 3528 & S. 2460-Every Prescription Conveyed Securely Act (e-prescribing).
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
S. 2554-Patient Right to Know Drug Prices Act; H.R. 5343-Prescription Transparency Act of 2018.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2017
In Q4, Brown Rudnick LLP lobbied for Prime Therapeutics , earning $30,000. The report was filed on Jan. 25, 2018.
Original Filing: 300938522.xml
Lobbying Issues
S.469-The Affordable and Safe Prescription Drug Importation Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 1316-The Prescription Drug Price Transparency Act (MAC); H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR); H.R. 1939 & S. 1044 - Ensuring Seniors Access to Local Pharmacies Act of 2017; S.637-Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 2212 & S. 974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; Issues relating to regulation of biosimilars; S. 771 & H.R. 1776-Improving Access to Affordable Prescription Drugs Act; H.R. 3528-Every Prescription Conveyed Securely Act (e-prescribing).Use of prescription drug coupons in federal programs and the ACA exchanges and their effects on insurance premiums.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2017
In Q3, Brown Rudnick LLP lobbied for Prime Therapeutics , earning $30,000. The report was filed on Oct. 20, 2017.
Original Filing: 300911744.xml
Lobbying Issues
S.469-The Affordable and Safe Prescription Drug Importation Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 1316-The Prescription Drug Price Transparency Act (MAC); H.R. 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act (DIR); H.R. 1939 & S. 1044 - Ensuring Seniors Access to Local Pharmacies Act of 2017; S.637-Creating Transparency to Have Drug Rebates Unlocked Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 2212 & S. 974-The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; H.R. 2999-Patients' Access to Treatments Act of 2017 (specialty tier cosharing); Issues relating to regulation of biosimilars;
Agencies Lobbied
U.S. Senate U.S. House of Representatives
2nd Quarter, 2017
In Q2, Brown Rudnick LLP lobbied for Prime Therapeutics , earning $30,000. The report was filed on July 19, 2017.
Original Filing: 300891718.xml
Lobbying Issues
S.469-The Affordable and Safe Prescription Drug Importation Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 1316-The Prescription Drug Price Transparency Act; S.637-Creating Transparency to Have Drug Rebates Unlocked Act of 2017; HR 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act; S.1003 relating to drug compendia & Medicaid drug payment. H.R. 1939 & S.1044-Ensuring Seniors Access to Local Pharmacies Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 2015-The FAST Generics Act; H.R. 2212 & S.974, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act; Issues relating to biosimilars and specialty pharmacy; H.R. 749 - The Lower Drug Costs Through Competition Act; H.R. 1776 & S. 771-Improving Access to Affordable Prescription Drugs Act; H.R. 2430 & S. 934-FDA Reauthorization Act of 2017; H.R. 1628-The American Health Care Act of 2017.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
1st Quarter, 2017
In Q1, Brown Rudnick LLP lobbied for Prime Therapeutics , earning $30,000. The report was filed on April 20, 2017.
Original Filing: 300874407.xml
Lobbying Issues
S.469-The Affordable and Safe Prescription Drug Importation Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
H.R. 1316-The Prescription Drug Price Transparency Act; S.637-Creating Transparency to Have Drug Rebates Unlocked Act of 2017; HR 1038 & S.413-Improving Transparency and Accuracy in Medicare Part D Drug Spending Act; Issues relating to Medicare Part D cash price disclosure
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
HR 1628-American Health Care Act of 2017; H.R. 2051 - The FAST Generics Act; HR 749 - The Lower Drug Costs Through Competition Act; Reauthorization of the Generic Durg User Fee Act; Issues relating to biosimilars and speciality pharmacy; HR 1776 & S. 771- Improving Access to Affordable Prescription Drugs Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2016
In Q4, Brown Rudnick LLP lobbied for Prime Therapeutics , earning $30,000. The report was filed on Jan. 21, 2017.
Original Filing: 300854204.xml
Lobbying Issues
HR 793 & S. 1190 - Ensuring Seniors Access to Local Pharmacies Act; H.R. 244 -The MAC Transparency Act; HR 34 - Century Cures Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Issues relating to biosimilars and Part D preferred pharmacy networks; CMS Proposed Guidance on Direct and Indirect Remuneration (DIR) and Pharmacy Price Concessions; H.R.4062 - Protecting Seniors Access to Proper Care Act of 2015; HR 5951-Improving Transparency and Accuracy in Medicare Part D Spending Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
3rd Quarter, 2016
In Q3, Brown Rudnick LLP lobbied for Prime Therapeutics , earning $30,000. The report was filed on Oct. 20, 2016.
Original Filing: 300834705.xml
Lobbying Issues
HR 793 & S. 1190 - Ensuring Seniors Access to Local Pharmacies Act; H.R. 244 -The MAC Transparency Act; HR 4981 -The Opioid Use Disorder Treatment Expansion and Modernization Act; HR 4599 - Reducing Unused Medications Act of 2016; S. 2256 - Co-Prescribing Saves Lives; HR 3680 - Co-Prescribing to Reduce Overdoses Act of 2016; S. 524 Comprehensive Addiction and Recovery Act (CARA)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Issues relating to biosimilars and Part D preferred pharmacy networks; CMS Proposed Guidance on Direct and Indirect Remuneration (DIR) and Pharmacy Price Concessions; H.R.4062 - Protecting Seniors Access to Proper Care Act of 2015; HR 5951-Improving Transparency and Accuracy in Medicare Part D Spending Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
2nd Quarter, 2016
In Q2, Brown Rudnick LLP lobbied for Prime Therapeutics , earning $30,000. The report was filed on July 19, 2016.
Original Filing: 300813219.xml
Lobbying Issues
HR 793 & S. 1190 - Ensuring Seniors Access to Local Pharmacies Act; H.R. 244 -The MAC Transparency Act; HR 4981 -The Opioid Use Disorder Treatment Expansion and Modernization Act; HR 4599 - Reducing Unused Medications Act of 2016; S. 2256 - Co-Prescribing Saves Lives; HR 3680 - Co-Prescribing to Reduce Overdoses Act of 2016; S. 524 Comprehensive Addiction and Recovery Act (CARA)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Issues relating to biosimilars and Part D preferred pharmacy networks; CMS Proposed Guidance on Direct and Indirect Remuneration (DIR) and Pharmacy Price Concessions
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
1st Quarter, 2016
In Q1, Brown Rudnick LLP lobbied for Prime Therapeutics , earning $30,000. The report was filed on April 14, 2016.
Original Filing: 300791163.xml
Lobbying Issues
HR 793 & S. 1190 - Ensuring Seniors Access to Local Pharmacies Act; H.R. 244, the MAC Transparency Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Federal policy relating to prescription drug abuse and preferred pharmacy networks
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
4th Quarter, 2015
In Q4, Brown Rudnick LLP lobbied for Prime Therapeutics , earning $30,000. The report was filed on Jan. 15, 2016.
Original Filing: 300773070.xml
Lobbying Issues
HR 793 - Ensuring Seniors Access to Local Pharmacies Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Medicare Part D policy relating to the Medication Therapy Management program, prescription drug abuse and preferred pharmacy networks.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
3rd Quarter, 2015
In Q3, Brown Rudnick LLP lobbied for Prime Therapeutics , earning $30,000. The report was filed on Oct. 19, 2015.
Original Filing: 300757396.xml
Lobbying Issues
HR 793 - Ensuring Seniors Access to Local Pharmacies Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Issues relating to prescription drug abuse in the Medicare Part D prescription drug program.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Implementation of the Biologics Price Competition and Innovation Act (BPCIA); CMS Proposed Rule {CMS-1631-P} RIN 0938-AS40 - Revisions to Payment Policies under the Physician Fee Schedule and Other Revisions to Part B for CY 2016
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
2nd Quarter, 2015
In Q2, Brown Rudnick LLP lobbied for Prime Therapeutics , earning $30,000. The report was filed on July 14, 2015.
Original Filing: 300734256.xml
Lobbying Issues
HR 793 - Ensuring Seniors Access to Local Pharmacies Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Issues relating to prescription drug abuse in the Medicare Part D prescription drug program.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Implementation of the Biologics Price Competition and Innovation Act (BPCIA)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
1st Quarter, 2015
In Q1, Brown Rudnick LLP lobbied for Prime Therapeutics , earning $30,000. The report was filed on April 17, 2015.
Original Filing: 300719175.xml
Lobbying Issues
HR 793 - Ensuring Seniors Access to Local Pharmacies Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Issues relating to prescription drug abuse in the Medicare Part D prescription drug program. Implementation of the Biologics Price Competition and Innovation Act (BPCIA)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
4th Quarter, 2014
In Q4, Brown Rudnick LLP lobbied for Prime Therapeutics , earning $30,000. The report was filed on Jan. 20, 2015.
Original Filing: 300706522.xml
Lobbying Issues
HR 4577 - Ensuring Seniors Access to Local Pharmacies Act of 2014
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Issues relating to generic pharmaceutical utilization and prescription drug abuse under the Medicare Part D prescription drug program. Implementation of the Biologics Price Competition and Innovation Act (BPCIA)
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
3rd Quarter, 2014
In Q3, Brown Rudnick LLP lobbied for Prime Therapeutics , earning $30,000. The report was filed on Oct. 17, 2014.
Original Filing: 300680783.xml
Lobbying Issues
Issues relating to prescription drug abuse and diversion; HR 4577 - Ensuring Seniors Access to Local Pharmacies Act of 2014
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
Lobbying Issues
Issues relating to specialty pharmacy. Implementation of the Biologics Price Competition and Innovation Act (BPCIA) relating to biosimilar naming.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Centers For Medicare and Medicaid Services (CMS)
2nd Quarter, 2014
In Q2, Brown Rudnick LLP lobbied for Prime Therapeutics , earning $30,000. The report was filed on July 18, 2014.
Original Filing: 300661678.xml
Lobbying Issues
Issues relating to generic pharmaceutical utilization; HR 4577 - Ensuring Seniors Access to Local Pharmacies Act of 2014
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS),
Lobbying Issues
Issues relating to speciality pharmacy.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2014
In Q1, Brown Rudnick LLP lobbied for Prime Therapeutics , earning $30,000. The report was filed on April 15, 2014.
Original Filing: 300635773.xml
Lobbying Issues
Issues relating to generic pharmaceutical utilization
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS),
Lobbying Issues
CMS proposes program changes for Medicare Advantage and Prescription Drug Benefit
Programs for Contract Year 2015 (CMS-4159-P); Issues relating to specialty pharmacy and Part D medication therapy management program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
4th Quarter, 2013
In Q4, Brown Rudnick LLP lobbied for Prime Therapeutics , earning $20,000. The report was filed on Jan. 16, 2014.
Original Filing: 300616508.xml
Lobbying Issues
Issues relating to generic pharmaceutical utilization MMM; Issues relating to the speciality tier drug category and prescription drug abuse in the medicare Part D program; The Medicare Prescription Drug Diversion and Abuse Prevention Act.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS),
Lobbying Issues
Issues relating to prescription drug misuse by Medicare beneficiaries and Medicare Part D prescription drug plans.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
3rd Quarter, 2013
In Q3, Brown Rudnick LLP lobbied for Prime Therapeutics , earning $20,000. The report was filed on Oct. 18, 2013.
Original Filing: 300599926.xml
Lobbying Issues
HR 460: Patients' Access to Treatments Act of 2013
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS),
Lobbying Issues
Issues relating to prescription drug misuse by Medicare beneficiaries and Medicare Part D prescription drug plans.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2013
In Q2, Brown Rudnick LLP lobbied for Prime Therapeutics , earning $20,000. The report was filed on July 18, 2013.
Original Filing: 300575247.xml
Lobbying Issues
P.L 111-148 - The Affordable Care Act implementation relating to pharmacy claims of QHP enrollees.
Agencies Lobbied
U.S. House of Representatives U.S. Senate Centers For Medicare and Medicaid Services (CMS),
Lobbying Issues
-S.867 Medicare Prescription Drug Program Integrity and Transparency Act of 2013
-Issues relating to price negotiation and preferred pharmacy networks in the Medicare Part D program.
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2013
In Q1, Brown Rudnick LLP lobbied for Prime Therapeutics , earning $20,000. The report was filed on April 18, 2013.
Original Filing: 300553229.xml
Lobbying Issues
P.L 111-148 - The Affordable Care Act implementation relating to cost-sharing subsidies (RIN: 0938 -AR74) and the multi-state plan program (RIN: 3206- AM47)
Agencies Lobbied
U.S. House of Representatives U.S. Senate Office of Personnel Management (OPM) Centers For Medicare and Medicaid Services (CMS)
4th Quarter, 2012
In Q4, Brown Rudnick LLP lobbied for Prime Therapeutics , earning $20,000. The report was filed on Jan. 18, 2013.
Original Filing: 300535421.xml
Lobbying Issues
P.L 111-148 - The Affordable Care Act implementation relating to the essential health benefits package, exchange establishment, cost-sharing subsidies and the multi-state plan program; S. 1058 - Pharmacy Competition and Consumer Choice Act; H.R. 4215 - Medicare Pharmacy Transparency and Fair Auditing Act; H.R. 1971 & S. 1058 - Pharmacy Competition and Consumer Choice Act of 2011
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
3rd Quarter, 2012
In Q3, Brown Rudnick LLP lobbied for Prime Therapeutics , earning $20,000. The report was filed on Oct. 17, 2012.
Original Filing: 300508352.xml
Lobbying Issues
P.L 111-148 - The Affordable Care Act relating to the essential health benefits package and exchange establishment; S. 1058 - Pharmacy Competition and Consumer Choice Act; H.R. 4215 - Medicare Pharmacy Transparency and Fair Auditing Act; H.R. 5651 & S. 2516 & S. 3187 FDA Safety and Innovation Act; H.R. 1971 & S. 1058 - Pharmacy Competition and Consumer Choice Act of 2011
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
Lobbying Issues
S. 1789 - 21st Century Postal Service Act of 2012
H.R. 2309 - Postal Reform Act of 2011
Agencies Lobbied
U.S. House of Representatives U.S. Senate
2nd Quarter, 2012
In Q2, Brown Rudnick LLP lobbied for Prime Therapeutics , earning $20,000. The report was filed on July 18, 2012.
Original Filing: 300488276.xml
Lobbying Issues
P.L 111-148 - The Affordable Care Act relating to the essential health benefits package and exchange establishment; S. 1058 - Pharmacy Competition and Consumer Choice Act; H.R. 4215 - Medicare Pharmacy Transparency and Fair Auditing Act; H.R. 5651 & S. 2516 & S. 3187 FDA Safety and Innovation Act; H.R. 1971 & S. 1058 - Pharmacy Competition and Consumer Choice Act of 2011
Agencies Lobbied
U.S. House of Representatives U.S. Senate Health & Human Services - Dept of (HHS)
Lobbying Issues
S. 1789 - 21st Century Postal Service Act of 2012
H.R. 2309 - Postal Reform Act of 2011
Agencies Lobbied
U.S. House of Representatives U.S. Senate
1st Quarter, 2012
In Q1, Brown Rudnick LLP lobbied for Prime Therapeutics , earning $20,000. The report was filed on April 17, 2012.
Original Filing: 300463606.xml
Lobbying Issues
P.L 111-148 - The Affordable Care Act relating to the essential health benefits package and exchange establishment
S. 1058 - Pharmacy Competition and Consumer Choice Act
Agencies Lobbied
U.S. House of Representatives U.S. Senate
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate